From Cradle to Grave: The Chromatographic (Analytical) Method Life Cycle
The Chromatographic Society and Joint Pharmaceutical Analysis Group have announced a one‑day meeting titled From Cradle to Grave: The Chromatographic (Analytical) Method Life Cycle. The meeting will be held at Burlington House, London, UK, on Thursday 10 May 2018.
Photo Credit: Marius_Comanescu/Shutterstock.com
The Chromatographic Society and Joint Pharmaceutical Analysis Group have announced a oneâday meeting titled From Cradle to Grave: The Chromatographic (Analytical) Method Life Cycle. The meeting will be held at Burlington House, London, UK, on Thursday 10 May 2018.
The meeting aims to provide clear insights into successful strategies in critical areas including method development, validation, transfer, and life cycle management in the pharmaceutical industry, and the latest regulatory expectations, specifically quality-by-design (QbD) and permitted chromatographic method changes according to main pharmacopoeias.
The presentations will be delivered by highly regarded international speakers from industry, regulators, and the chromatography industry. The calibre of the speakers, combined with a fully integrated exhibition and vendor presentation programme, will deliver a highly interesting and well attended event, according to the organizers. The meeting will provide attendees with a unique means of sharing real experiences with other professionals and will provide excellent networking opportunities. The meeting has been separated into four separate sessions spread across the day.
Session 1:
- Melissa Hanna-Brown (Pfizer, Sandwich, UK)-State-of-the-art Method Development Concepts and Tools as Part of the Analytical Life Cycle
- Elena Razzano (MHRA, London, UK)-QbD: Update on Current QbD Regulatory Expectations. Including the application of analytical QbD, ICH Q12 life cycle management, and filing expectations
Session 2:
- Sophie Bailes (AstraZeneca R&D, Macclesfield, UK)-How QbD in the Pharmaceutical Industry has Facilitated New Ways of Developing Robust LC Methods Under Challenging Timelines
Session 3:
- Claudio Brunelli (Pfizer, Sandwich, UK)-The Current Status and Latest Developments in SFC. Addressing the question “Is modern SFC ready for the QC laboratory?”
- Vendor sponsored short talks
Session 4:
- Stuart Williams (Novartis Pharma, Grimsby, UK)-The Complex Topic of Recent Regional Health Authority Requirements
- Katrin Liebelt (Novartis Pharma AG, Basel, Switzerland)-The Latest Requirements, Concepts, and Approaches for Analytical Validation and Transfer Strategies
There will also be a poster presentation and interested presenters should submit an abstract to the organizers by 20 April 2018.
ChromSoc student bursaries are available for this event. For further details, please visit: www.chromsoc.com/academic-support.aspx
Registration and further information on the meeting is available at: www.jpag.org/101 and www.chromsoc.com/ChromsocEvents.aspx
For further information on the submission or abstracts, sponsorship, or payment details, e-mail: adrian.clarke@novartis.com
GC–TOF-MS Finds 250 Volatile Compounds in E-Cigarette Liquids
November 1st 2024A study has used gas chromatography coupled to a time-of-flight mass spectrometer to build an electron ionization mass spectra database of more than 250 chemicals classified as either volatile or semi-volatile compounds. An additional, confirmatory layer of liquid chromatography–mass spectrometry analysis was subsequently performed.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
Multivariate Design of Experiments for Gas Chromatographic Analysis
November 1st 2024Recent advances in green chemistry have made multivariate experimental design popular in sample preparation development. This approach helps reduce the number of measurements and data for evaluation and can be useful for method development in gas chromatography.
